Download PDF
Synfacts 2010(7): 0740-0740  
DOI: 10.1055/s-0029-1220017
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of TS-071

Contributor(s): Philip Kocienski
et al. H. Kakinuma*
Taisho Pharmaceutial Co., Saitama-shi, Japan
Further Information

Publication History

Publication Date:
22 June 2010 (online)

    Permissions and Reprints

Significance

TS-071 is a C-thioglycoside that selectively inhibits SGLT2 (sodium-dependent ­glucose cotransporter 2) and consequently aids normalization of plasma glucose levels in diabetics by preventing renal glucose absorption and promoting glucose excretion in the urine. It is related to dapagliflozin, a selective SGLT2 inhibitor in phase III clinical trials for the treatment of type 2 diabetes.